Literature DB >> 9649044

Laparoscopic cholecystectomy for the various types of gallbladder inflammation: a prospective trial.

S Eldar1, E Sabo, E Nash, J Abrahamson, I Matter.   

Abstract

Laparoscopic cholecystectomy (LC), the procedure of choice for elective cholelithiasis, is now also used in the management of acute cholecystitis. In the various types of gallbladder disease, favorable and unfavorable conditions may influence the conversion and complication rates. Information about these conditions may help elucidate the optimal circumstances for LC or indicate when the procedure is best avoided. We attempted to perform emergency LC on 215 patients with acute cholecystitis. The procedure was successful in 171 patients (79.5%), and conversion to open cholecystectomy (OC) was needed in 44 (20.5%). Complications occurred in 37 patients (17%). Uncomplicated acute cholecystitis was associated with age <50 years, duration of complaint <48 h, temperature <38.5 degrees C, a nonpalpable gallbladder, and an alkaline phosphatase >100 U/L. Acute gangrenous cholecystitis was associated with a negative gallbladder history, other associated diseases, temperature >38.5 degrees C, a palpable gallbladder, and serum bilirubin levels <1 mg/dl. Hydrops was associated with a temperature <38 degrees C and a leukocyte count of >12,000/cc3, and empyema of the gallbladder was associated with duration of complaint >48 h and a palpable gallbladder. The conversion rate of acute gangrenous cholecystitis (40%) was significantly higher than that of uncomplicated acute cholecystitis (8%) (p < 0.00001, odds ratio=7.7), as well as that of empyema of the gallbladder (12.5%) (p=0.005, odds ratio=4.7). The conversion from LC to OC in uncomplicated acute cholecystitis was associated with male sex and with duration of complaint >24 h, and in gangrenous cholecystitis with age >60 years, a nonpalpable gallbladder, and a leukocyte count of >15,000/cc3. The complication rates of acute cholecystitis, hydrops, empyema of the gallbladder, and gangrenous cholecystitis were 16%, 7%, 22%, and 21%, respectively (p = NS). The total complication rate in acute cholecystitis tended to be associated with a duration of complaint >48 h and in gangrenous cholecystitis with male sex, age >60 years, other associated disease, larger bile stones, and elevated serum bilirubin levels. Generally, LC is safe in all forms of cholecystitis, with acceptably low conversion and complication rates, excluding gangrenous cholecystitis. In gangrenous cholecystitis, a conversion rate of approximately 40% is expected. Predictors of conversion and complications may be particularly helpful in planning the laparoscopic approach to acute gangrenous cholecystitis. Patients >60 years of age, with a nonpalpable gallbladder and with a leukocyte count >15,000/cc3, frequently need conversion. In men >60 years old, with other associated disease, with larger bile stones, and with elevated serum bilirubin levels, complications are frequently expected. Under these conditions, laparoscopic approach should be undertaken by especially experienced teams, or OC should be considered.

Entities:  

Mesh:

Year:  1998        PMID: 9649044

Source DB:  PubMed          Journal:  Surg Laparosc Endosc        ISSN: 1051-7200


  29 in total

1.  Surgical outcomes of laparoscopic cholecystectomy for severe acute cholecystitis.

Authors:  Ji Hun Kim; Jeong Woon Kim; In Ho Jeong; Tae Yong Choi; Byung Moo Yoo; Jin Hong Kim; Myung Wook Kim; Wook Hwan Kim
Journal:  J Gastrointest Surg       Date:  2008-03-08       Impact factor: 3.452

2.  Laparoscopic cholecystectomy for acute cholecystitis: safe implementation of successful strategies to reduce conversion rates.

Authors:  Shiong-Wen Low; Shridhar Ganpathi Iyer; Stephen K-Y Chang; Kenneth S W Mak; Victor Tswen Wen Lee; Krishnakumar Madhavan
Journal:  Surg Endosc       Date:  2009-03-05       Impact factor: 4.584

3.  The outcome of early laparoscopic surgery to treat acute cholecystitis: a single-center experience.

Authors:  Fatih Ciftci; Ibrahim Abdurrahman; Sadullah Girgin
Journal:  Int J Clin Exp Med       Date:  2015-03-15

4.  What is the optimal time for laparoscopic cholecystectomy in gallbladder empyema?

Authors:  Yong Jin Kwon; Byung Kyu Ahn; Hwon Kyum Park; Kwang Soo Lee; Kyeong Geun Lee
Journal:  Surg Endosc       Date:  2013-05-04       Impact factor: 4.584

5.  Is a drain necessary routinely after laparoscopic cholecystectomy for an acutely inflamed gallbladder? A retrospective analysis of 457 cases.

Authors:  Eun Young Kim; Young Kyoung You; Dong Goo Kim; Soo Ho Lee; Jae Hyun Han; Sung Kyun Park; Gun Hyung Na; Tae Ho Hong
Journal:  J Gastrointest Surg       Date:  2014-01-17       Impact factor: 3.452

6.  Impact of Jaundice on Outcomes Following Emergency Laparoscopic Cholecystectomy in Patients with Choledocholithiasis.

Authors:  Benjamin R Poh; Paul A Cashin; Daniel G Croagh
Journal:  World J Surg       Date:  2018-10       Impact factor: 3.352

7.  Outcome of conservative percutaneous cholecystostomy in high-risk patients with acute cholecystitis and risk factors leading to surgery.

Authors:  Won Seok Jang; Jun Uk Lim; Kwang Ro Joo; Jae Myung Cha; Hyun Phil Shin; Sun Hyung Joo
Journal:  Surg Endosc       Date:  2014-12-09       Impact factor: 4.584

8.  Laparoscopic cholecystectomy in empyema of gall bladder: An experience at Liaquat University Hospital, Jamshoro, Pakistan.

Authors:  Arshad Malik; Abdul Aziz Laghari; K Altaf Hussain Talpur; Aisha Memon; Qasim Mallah; Jan Mohammad Memon
Journal:  J Minim Access Surg       Date:  2007-04       Impact factor: 1.407

9.  Laparoscopic cholecystectomy for acute cholecystitis.

Authors:  Angel Iliev Popkharitov
Journal:  Langenbecks Arch Surg       Date:  2008-02-26       Impact factor: 3.445

10.  Identification of risk factors for an unfavorable laparoscopic cholecystectomy course after endoscopic retrograde cholangiography in the treatment of choledocholithiasis.

Authors:  S C Donkervoort; O van Ruler; L M Dijksman; A A van Geloven; E G Pierik
Journal:  Surg Endosc       Date:  2009-08-26       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.